CNIPA.AI

Company patentsCompare

HEAD TO HEAD

Hengrui PharmaPetroChina

Technology portfolios compared in the same window and counting units. Scale is compared only within the same field or subclass.

Same window · published 2025-01-01 — 2025-12-31Some name or date coverage is incomplete; affected counts are lower bounds

This is a structural comparison of collected portfolios. The same requested window does not establish equal entity scope, covered months or industry; no competitive ranking is inferred.

Applicant-name coverage differs. The counts below cover only the listed names and do not represent complete company portfolios.

Hengrui Pharma: Applicant names included in these statistics — JIANGSU HENGRUI MEDICINE CO · JIANGSU HENGRUI MEDICINE CO LTD · JIANGSU HENGRUI PHARMACEUTICALS CO LTDReviewed names not covered — JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. · 江苏恒瑞医药股份有限公司

PetroChina: Applicant names included in these statistics — PETROCHINA CO LTDReviewed names not covered — PETROCHINA COMPANY LIMITED · 中国石油天然气股份有限公司

Publications
618
Invention share
66%
Concentration
1.23
Green technology
—
Publications
6,110
Invention share
95%
Concentration
0.25
Green technology
—
0.04Field similarity
Cosine similarity of application counts across 35 fields. 1 is identical, 0 is no overlap.

01Technology field mirror

The 12 fields with the largest combined share. Share shows structure; count shows scale.

Technology field mirror
Hengrui PharmaTechnology fieldPetroChina
93%
Pharmaceuticals
0%
49.7%
Organic fine chemistry
3.4%
34.3%
Biotechnology
0.6%
0%
Civil engineering
31.5%
0.5%
Measurement
22.9%
0%
Computer technology
22.4%
0%
Basic materials chemistry
11.9%
0%
IT methods for management
9.5%
0.3%
Chemical engineering
9%
0.3%
Macromolecular chemistry, polymers
6.9%
2%
Analysis of biological materials
3%
0%
Environmental technology
4.2%

Inspect one technology field

Inspect collected applications, portfolio share and supporting publications within one field. A technology overlap does not establish that companies in different industries are direct competitors.

One application may belong to multiple fields, so shares can sum to more than 100%. Drill-down lists publications; an application publication and its grant may appear separately.

02Same problem: shared IPC subclasses

The 10 subclasses in every company's top 60 with the most combined applications. Scale is compared within a subclass, never across different business scopes.

G01NAnalysing materials
Hengrui Pharma14
PetroChina752
B01J
Hengrui Pharma2
PetroChina385
C07DHeterocyclic compounds
Hengrui Pharma270
PetroChina23
C08FAddition polymers
Hengrui Pharma1
PetroChina284
C07C
Hengrui Pharma45
PetroChina167
C12NMicroorganisms, enzymes
Hengrui Pharma70
PetroChina27
C08G
Hengrui Pharma2
PetroChina63
C07F
Hengrui Pharma10
PetroChina36

03Where each one leans

Observed emphasis within each company’s collected top-60 IPC subclasses. A dash for another company means outside its top-60 list, not zero applications or a market gap. Incomplete coverage can also change the ordering.

Hengrui Pharma

  • A61K
    Hengrui Pharma
    539
    PetroChina
    —
  • A61P
    Hengrui Pharma
    504
    PetroChina
    —
  • C07DHeterocyclic compounds
    Hengrui Pharma
    270
    PetroChina
    23
  • C07K
    Hengrui Pharma
    196
    PetroChina
    —
  • C12NMicroorganisms, enzymes
    Hengrui Pharma
    70
    PetroChina
    27
  • C07C
    Hengrui Pharma
    45
    PetroChina
    167

PetroChina

  • E21B
    Hengrui Pharma
    —
    PetroChina
    1,882
  • G06FData processing
    Hengrui Pharma
    —
    PetroChina
    1,114
  • G01NAnalysing materials
    Hengrui Pharma
    14
    PetroChina
    752
  • G06QBusiness data processing
    Hengrui Pharma
    —
    PetroChina
    577
  • G01V
    Hengrui Pharma
    —
    PetroChina
    571
  • B01J
    Hengrui Pharma
    2
    PetroChina
    385

04Publication rhythm

Hengrui PharmaPetroChinaPublications per period
Publications per period
PeriodHengrui PharmaPetroChina
2025-01≥33 (partial coverage)≥410 (partial coverage)
2025-02≥41 (partial coverage)≥695 (partial coverage)
2025-03≥82 (partial coverage)≥574 (partial coverage)
2025-04≥52 (partial coverage)≥558 (partial coverage)
2025-05≥61 (partial coverage)≥1,028 (partial coverage)
2025-06≥50 (partial coverage)≥674 (partial coverage)
2025-07≥57 (partial coverage)≥299 (partial coverage)
2025-08≥44 (partial coverage)≥143 (partial coverage)
2025-09≥51 (partial coverage)≥486 (partial coverage)
2025-10≥47 (partial coverage)≥403 (partial coverage)
2025-11≥50 (partial coverage)≥383 (partial coverage)
2025-12≥50 (partial coverage)≥457 (partial coverage)

Empty dashed outlines mark uncollected periods. Hatched bars and ≥ counts mark partial coverage.

Publication timing follows examination and publication cycles, not R&D intensity.

What makes it comparableThe same publication window and counting units. Companies with different windows are not put in one comparison.

What is not comparableGroup totals. Business and entity scopes differ; compare scale within a field or subclass.

Not a rankingSimilarity and shares describe structure, not patent value, quality or technical leadership.